



- (51) **International Patent Classification:**
A61K 38/18 (2006.01) *C12Q 1/68* (2006.01)
- (21) **International Application Number:**
PCT/US2014/039129
- (22) **International Filing Date:**
22 May 2014 (22.05.2014)
- (25) **Filing Language:** English
- (26) **Publication Language:** English
- (30) **Priority Data:**
61/826,975 23 May 2013 (23.05.2013) US
61/936,471 6 February 2014 (06.02.2014) US
61/974,279 2 April 2014 (02.04.2014) US
- (71) **Applicants:** **FIVE PRIME THERAPEUTICS, INC.** [US/US]; Two Corporate Drive, South San Francisco, California 94080 (US). **GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 2) LIMITED** [GB/GB]; 980 Great West Road, Brentford Middlesex TW8 9GS (GB).
- (72) **Inventors:** **BELLOVIN, David**; Two Corporate Drive, South San Francisco, California 94080 (US). **BAKER, Kevin**; Two Corporate Drive, South San Francisco, California 94080 (US). **BRENNAN, Thomas**; Two Corporate Drive, South San Francisco, California 94080 (US). **PAN-DITE, Arundathy Nirmalini**; 980 Great West Road, Brentford Middlesex TW8 9GS (GB). **MOOKERJEE, Bijoyesh**; 980 Great West Road, Brentford Middlesex TW8 9GS (GB). **DEYOUNG, Maurice P.**; 980 Great West Road, Brentford Middlesex TW8 9GS (GB). **KUMAR,**

Rakesh; 980 Great West Road, Brentford Middlesex TW8 9GS (GB).

(74) **Agent:** **SCARR, Rebecca B.**; 2275 Deming Way, Suite 310, Middleton, Wisconsin 53562 (US).

(81) **Designated States** (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) **Designated States** (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- *without international search report and to be republished upon receipt of that report (Rule 48.2(g))*
- *with sequence listing part of description (Rule 5.2(a))*

(54) **Title:** METHODS OF TREATING CANCER

(57) **Abstract:** Methods of treating cancers comprising administering a fibroblast growth factor receptor 1 (FGFR1) extracellular domain (ECD) and/or an FGFR1 ECD fusion molecule are provided. Methods of treating cancers comprising administering a fibroblast growth factor receptor 1 (FGFR1) extracellular domain (ECD) and/or an FGFR1 ECD fusion molecule and at least one anti-an-

